Comparative Pharmacology
Head-to-head clinical analysis: THEOCLEAR L A 130 versus THEOCLEAR L A 260.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOCLEAR L A 130 versus THEOCLEAR L A 260.
THEOCLEAR L.A.-130 vs THEOCLEAR L.A.-260
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Theophylline causes bronchodilation by inhibiting phosphodiesterase, increasing cAMP levels, and antagonizing adenosine receptors.
130 mg orally every 12 hours; extended-release tablet.
Theophylline (THEOCLEAR L.A.-260) 260 mg orally every 12 hours. Adjust dose based on serum theophylline concentrations to achieve 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life is 3-8 hours in healthy adults (mean 5-6 hours). It is prolonged in patients with hepatic cirrhosis, heart failure, or COPD (up to 30 hours) and in neonates (20-30 hours). Smoking induces metabolism, reducing half-life to 1-4 hours.
Terminal elimination half-life is approximately 6-12 hours in adults (range 3-12 hours, prolonged in congestive heart failure, liver disease, and with certain drugs). In neonates, half-life is prolonged (24-36 hours).
Approximately 90% of theophylline is eliminated hepatically via CYP1A2 and CYP3A4 metabolism; renal excretion of unchanged drug accounts for about 10% in adults, but may increase to 50% in neonates. Biliary/fecal elimination is negligible.
Renal elimination of unchanged drug (10%) and hepatic metabolism (90%). Metabolism is primarily via CYP1A2 and CYP3A4, with metabolites excreted in urine (about 80% of the dose) and feces (about 20%).
Category C
Category C
Bronchodilator
Bronchodilator